AIkido Pharma (NASDAQ:AIKI) Stock Price Crosses Above Two Hundred Day Moving Average of $2.22

AIkido Pharma Inc. (NASDAQ:AIKI) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.22 and traded as high as $2.50. AIkido Pharma shares last traded at $2.45, with a volume of 5,906 shares trading hands.

AIkido Pharma Trading Down 2.0 %

The firm has a 50-day simple moving average of $2.17 and a two-hundred day simple moving average of $2.22. The company has a market capitalization of $13.44 million, a price-to-earnings ratio of -0.63 and a beta of 0.93.

Institutional Trading of AIkido Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AIKI. Two Sigma Advisers LP grew its holdings in shares of AIkido Pharma by 630.0% during the 3rd quarter. Two Sigma Advisers LP now owns 86,700 shares of the business services provider’s stock worth $593,000 after purchasing an additional 74,824 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of AIkido Pharma by 26.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 57,849 shares of the business services provider’s stock worth $396,000 after purchasing an additional 12,111 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of AIkido Pharma during the 3rd quarter worth approximately $367,000. Finally, Jane Street Group LLC acquired a new stake in shares of AIkido Pharma during the 3rd quarter worth approximately $77,000. Institutional investors and hedge funds own 10.88% of the company’s stock.

AIkido Pharma Company Profile

AIkido Pharma Inc, a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.